# NCT03248492 (NCT03248492)

> A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03248492
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Daiichi Sankyo
- Conditions: Breast Cancer
- Interventions: DS-8201a
- Enrollment: 253
- Primary outcome: Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

## Commentary we found

- Podcasts: 30
- YouTube: 28
- X threads: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03248492

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03248492", "email": "<work email>"}; the inbox owner confirms by the emailed link.